Tirdzniecība Alimera Sciences, Inc. - ALIM CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Starpība | 0.23 | ||||||||
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
Nakts laika nodeva | 21:00 (UTC) | ||||||||
Min. tirgotais daudzums | 1 | ||||||||
Valūta | USD | ||||||||
Drošības rezerve | 20% | ||||||||
Fondu birža | United States of America | ||||||||
Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Iepriekš. aizvērt* | 2.65 |
Atvērt* | 2.6 |
Izmaiņas par 1 gadu* | -54.14% |
Dienas Diapazons* | 2.51 - 2.6 |
52 ned Diapazons | 1.30-7.92 |
Vidējais apjoms (10 dienas) | 3.73M |
Vidējais apjoms (3 mēneši) | 12.89M |
Tirgus Kapitalizācija | 19.59M |
Cenas/Peļņas Attiecība | -100.00K |
Izvietotās Akcijas | 7.40M |
Ieņēmumi | 55.78M |
EPS | -2.44 |
Dividende (Ienesīgums %) | N/A |
Beta | 1.40 |
Nākamās Peļņas Datums | Jul 25, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
---|---|---|---|---|---|---|
May 31, 2023 | 2.67 | 0.19 | 7.66% | 2.48 | 2.67 | 2.48 |
May 30, 2023 | 2.52 | 0.05 | 2.02% | 2.47 | 2.55 | 2.47 |
May 26, 2023 | 2.49 | 0.08 | 3.32% | 2.41 | 2.52 | 2.35 |
May 25, 2023 | 2.48 | -0.02 | -0.80% | 2.50 | 2.51 | 2.37 |
May 24, 2023 | 2.41 | 0.23 | 10.55% | 2.18 | 2.42 | 2.14 |
May 23, 2023 | 2.32 | -0.19 | -7.57% | 2.51 | 2.55 | 2.21 |
May 22, 2023 | 2.45 | 0.28 | 12.90% | 2.17 | 2.72 | 2.15 |
May 19, 2023 | 2.23 | 0.12 | 5.69% | 2.11 | 2.30 | 2.02 |
May 18, 2023 | 2.34 | -0.26 | -10.00% | 2.60 | 3.05 | 2.26 |
May 17, 2023 | 1.93 | 0.11 | 6.04% | 1.82 | 1.94 | 1.78 |
May 16, 2023 | 1.79 | 0.21 | 13.29% | 1.58 | 1.92 | 1.58 |
May 15, 2023 | 1.57 | -0.03 | -1.88% | 1.60 | 1.68 | 1.56 |
May 12, 2023 | 1.56 | -0.05 | -3.11% | 1.61 | 1.64 | 1.55 |
May 11, 2023 | 1.57 | 0.02 | 1.29% | 1.55 | 1.64 | 1.48 |
May 10, 2023 | 1.52 | -0.11 | -6.75% | 1.63 | 1.85 | 1.51 |
May 9, 2023 | 1.63 | -0.14 | -7.91% | 1.77 | 1.77 | 1.63 |
May 8, 2023 | 1.73 | -0.06 | -3.35% | 1.79 | 1.80 | 1.73 |
May 5, 2023 | 1.83 | -0.05 | -2.66% | 1.88 | 2.04 | 1.76 |
May 4, 2023 | 1.84 | 0.10 | 5.75% | 1.74 | 1.85 | 1.69 |
May 3, 2023 | 1.69 | 0.01 | 0.60% | 1.68 | 1.78 | 1.66 |
Alimera Sciences, Inc. Events
Laiks (UTC) (UTC) | Valsts | Notikums |
---|---|---|
Wednesday, July 12, 2023 | ||
Laiks (UTC) (UTC) 13:30 | Valsts US
| Notikums Alimera Sciences Inc Annual Shareholders Meeting Alimera Sciences Inc Annual Shareholders MeetingForecast -Previous - |
Tuesday, July 25, 2023 | ||
Laiks (UTC) (UTC) 12:30 | Valsts US
| Notikums Q2 2023 Alimera Sciences Inc Earnings Release Q2 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
Laiks (UTC) (UTC) 13:30 | Valsts US
| Notikums Q3 2023 Alimera Sciences Inc Earnings Release Q3 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kopējie ienākumi | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
Ienākumi | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
Cost of Revenue, Total | 7.977 | 7.03 | 6.941 | 6.626 | 4.308 |
Bruto Peļņa | 46.152 | 51.999 | 43.879 | 47.317 | 42.291 |
Kopējie Darbības Izdevumi | 65.769 | 57.438 | 51.321 | 59.217 | 58.035 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 38.858 | 35.843 | 32.036 | 38.958 | 38.042 |
Pētniecība un Attīstība | 16.228 | 13.778 | 9.668 | 10.992 | 11.274 |
Depreciation / Amortization | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
Neparedzēti Izdevumi (Ienākumi) | 0 | -1.792 | 0 | 1.766 | |
Darbības Izdevumi | -11.64 | 1.591 | -0.501 | -5.274 | -11.436 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -5.789 | -4.997 | -4.906 | -4.953 | -4.84 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -18.079 | -3.934 | -5.407 | -10.227 | -16.276 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Neto Ienākumi | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Atšķaidītie Neto Ienākumi | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Atšķaidītie Ienākumi par Akcijām | 6.99685 | 6.59524 | 5.11766 | 4.7702 | 5.91587 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -2.58788 | -0.6629 | -1.04325 | -2.18921 | 3.71002 |
Atšķaidītā Normalizētā Peļņa par Akciju | -2.58788 | -0.83951 | -1.04325 | -2.18921 | 3.90406 |
Other Operating Expenses, Total | |||||
Ārkārtas Posteņi Kopā | 0 | 0 | |||
Total Adjustments to Net Income | 0 | 38.33 | |||
Citi, Neto | -0.65 | -0.528 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kopējie ienākumi | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
Ienākumi | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
Cost of Revenue, Total | 2.028 | 2.125 | 2.006 | 2.166 | 1.68 |
Bruto Peļņa | 11.518 | 11.904 | 11.592 | 12.438 | 10.218 |
Kopējie Darbības Izdevumi | 16.848 | 16.137 | 17.009 | 16.578 | 16.045 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 9.975 | 9.099 | 9.856 | 9.81 | 10.093 |
Pētniecība un Attīstība | 4.164 | 4.23 | 4.483 | 3.932 | 3.583 |
Depreciation / Amortization | 0.681 | 0.683 | 0.664 | 0.67 | 0.689 |
Darbības Izdevumi | -3.302 | -2.108 | -3.411 | -1.974 | -4.147 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -1.68 | -1.621 | -1.567 | -1.345 | -1.256 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -4.968 | -3.781 | -5.245 | -3.098 | -5.955 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Neto Ienākumi | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Atšķaidītie Neto Ienākumi | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Atšķaidītie Ienākumi par Akcijām | 7.03223 | 7.00032 | 6.99658 | 6.99971 | 6.99074 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Atšķaidītā Normalizētā Peļņa par Akciju | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
Neparedzēti Izdevumi (Ienākumi) | 0 | 0 | 0 | ||
Citi, Neto | 0.014 | -0.052 | -0.267 | 0.221 | -0.552 |
Total Adjustments to Net Income | -0.014 |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 29.413 | 42.16 | 34.906 | 32.745 | 34.848 |
Nauda un Īstermiņa Ieguldījumi | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
Nauda un Ekvivalenti | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
Debitoru Parādu Kopsumma, Neto | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
Accounts Receivable - Trade, Net | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
Total Inventory | 1.605 | 2.679 | 2.746 | 1.39 | 2.405 |
Prepaid Expenses | 2.892 | 3.809 | 3.718 | 2.565 | 2.109 |
Other Current Assets, Total | 0.03 | 0.034 | 0.034 | 0.033 | 0.032 |
Total Assets | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
Property/Plant/Equipment, Total - Net | 3.92 | 4.493 | 2.358 | 2.047 | 1.355 |
Property/Plant/Equipment, Total - Gross | 7.981 | 7.923 | 6.305 | 5.858 | 4.967 |
Accumulated Depreciation, Total | -4.061 | -3.43 | -3.947 | -3.881 | -3.612 |
Intangibles, Net | 8.957 | 10.897 | 12.838 | 14.783 | 16.723 |
Other Long Term Assets, Total | 0.129 | 0.137 | 0.753 | 0.734 | 1.182 |
Total Current Liabilities | 39.732 | 12.592 | 12.348 | 12.048 | 10.234 |
Accounts Payable | 10.088 | 8.706 | 7.461 | 7.077 | 6.355 |
Accrued Expenses | 3.998 | 3.617 | 3.197 | 4.716 | 3.643 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 25.646 | 0.269 | 1.69 | 0.255 | 0.236 |
Other Current Liabilities, Total | |||||
Total Liabilities | 63.41 | 61.125 | 58.833 | 54.754 | 51.386 |
Total Long Term Debt | 18.683 | 43.08 | 42.922 | 38.752 | 38.178 |
Long Term Debt | 18.683 | 43.08 | 42.408 | 38.658 | 37.873 |
Capital Lease Obligations | 0.514 | 0.094 | 0.305 | ||
Other Liabilities, Total | 4.995 | 5.453 | 3.563 | 3.954 | 2.974 |
Total Equity | -20.808 | -2.605 | -7.978 | -4.445 | 2.722 |
Preferred Stock - Non Redeemable, Net | 19.227 | 19.227 | 19.227 | 30.344 | 30.344 |
Common Stock | 0.07 | 0.069 | 0.057 | 0.05 | 0.701 |
Additional Paid-In Capital | 378.238 | 377.229 | 365.83 | 350.117 | 346.108 |
Retained Earnings (Accumulated Deficit) | -415.388 | -397.281 | -392.539 | -383.863 | -373.42 |
Other Equity, Total | -2.955 | -1.849 | -0.553 | -1.093 | -1.011 |
Total Liabilities & Shareholders’ Equity | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
Total Common Shares Outstanding | 6.99551 | 6.93515 | 5.71937 | 4.96595 | 4.67193 |
Total Preferred Shares Outstanding | 0.6 | 0.6 | 0.6 | 0.61015 | 0.61015 |
Long Term Investments | 0.183 | 0.833 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 35.675 | 29.413 | 29.76 | 33.073 | 34.753 |
Nauda un Īstermiņa Ieguldījumi | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
Nauda un Ekvivalenti | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
Debitoru Parādu Kopsumma, Neto | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
Accounts Receivable - Trade, Net | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
Total Inventory | 1.215 | 1.605 | 1.786 | 1.656 | 2.452 |
Prepaid Expenses | 2.91 | 2.892 | 3.29 | 3.208 | 3.546 |
Other Current Assets, Total | 0.031 | 0.03 | 0.028 | 0.031 | 0.033 |
Total Assets | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
Property/Plant/Equipment, Total - Net | 3.757 | 3.92 | 3.87 | 3.938 | 4.343 |
Intangibles, Net | 8.479 | 8.957 | 9.446 | 9.935 | 10.419 |
Other Long Term Assets, Total | 0.131 | 0.129 | 0.118 | 0.126 | 0.134 |
Total Current Liabilities | 14.173 | 39.732 | 34.01 | 25.431 | 17.006 |
Accounts Payable | 9.669 | 10.088 | 8.706 | 7.614 | 6.604 |
Accrued Expenses | 4.241 | 3.998 | 3.661 | 3.316 | 3.046 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.263 | 25.646 | 21.643 | 14.501 | 7.356 |
Total Liabilities | 67.155 | 63.41 | 61.507 | 59.909 | 58.534 |
Total Long Term Debt | 44.312 | 18.683 | 22.492 | 29.297 | 36.245 |
Long Term Debt | 44.152 | 18.683 | 22.492 | 29.297 | 36.245 |
Capital Lease Obligations | 0.16 | ||||
Other Liabilities, Total | 8.67 | 4.995 | 5.005 | 5.181 | 5.283 |
Total Equity | -18.916 | -20.808 | -18.078 | -12.335 | -8.603 |
Preferred Stock - Non Redeemable, Net | 7.728 | 19.227 | 19.227 | 19.227 | 19.227 |
Common Stock | 0.074 | 0.07 | 0.07 | 0.07 | 0.07 |
Additional Paid-In Capital | 378.146 | 378.238 | 378.005 | 377.847 | 377.541 |
Retained Earnings (Accumulated Deficit) | -402.081 | -415.388 | -411.608 | -406.351 | -403.236 |
Other Equity, Total | -2.783 | -2.955 | -3.772 | -3.128 | -2.205 |
Total Liabilities & Shareholders’ Equity | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
Total Common Shares Outstanding | 7.39159 | 6.99551 | 6.99802 | 6.99546 | 6.99265 |
Total Preferred Shares Outstanding | 0.012 | 0.6 | 0.6 | 0.6 | 0.6 |
Long Term Investments | 0.197 | 0.183 | 0.235 | 0.502 | 0.282 |
Other Current Liabilities, Total |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Neto ienākumi/Sākuma Līnija | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Nauda no Darbības | -9.975 | -3.224 | -2.193 | -4.152 | -11.553 |
Nauda no Darbības | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
Deferred Taxes | 0.116 | 0.61 | 0.031 | 0.454 | -0.653 |
Bezskaidras Naudas Preces | 2.621 | -0.692 | 1.829 | 3.377 | 7.084 |
Cash Taxes Paid | 0.232 | 0.112 | 0.11 | 0.239 | 0.239 |
Samaksātie Procenti Naudā | 4.489 | 4.302 | 4.556 | 4.419 | 3.571 |
Izmaiņas Apgrozāmajā Kapitālā | 2.689 | -1.349 | -1.39 | -0.181 | -4.247 |
Nauda no Ieguldījumu Darbībām | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
Kapitālie Izdevumi | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
Nauda no Darbībām ar Finansēšanu | -0.302 | 9.823 | 3.882 | 0.869 | 0.95 |
Naudas Plūsma Finansēšanas Posteņos | -0.113 | 0 | -0.019 | -2.227 | -3.808 |
Akciju Izsniegšana (Atkāpšanās), Neto | 0.1 | 10.044 | 0.049 | 0.902 | 0.085 |
Parādu Izsniegšana (Atkāpšanās), Neto | -0.289 | -0.221 | 3.852 | 2.194 | 4.673 |
Ārvalstu Valūtas Ietekme | -0.708 | -0.676 | 0.714 | -0.159 | -0.248 |
Neto Izmaiņas Naudā | -11.24 | 5.302 | 1.783 | -3.616 | -11.026 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.968 | -18.107 | -14.327 | -9.07 | -5.955 |
Cash From Operating Activities | -2.209 | -9.975 | -9.724 | -7.811 | -6.213 |
Cash From Operating Activities | 0.681 | 2.706 | 2.023 | 1.359 | 0.689 |
Non-Cash Items | 0.507 | 2.621 | 2.095 | 1.318 | 1.027 |
Cash Taxes Paid | 0 | 0.232 | 0.224 | 0.182 | 0.018 |
Cash Interest Paid | 1.354 | 4.489 | 3.253 | 2.145 | 1.061 |
Changes in Working Capital | 1.571 | 2.689 | 0.485 | -1.418 | -1.974 |
Cash From Investing Activities | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
Capital Expenditures | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
Cash From Financing Activities | 9.998 | -0.302 | -0.109 | -0.164 | -0.062 |
Financing Cash Flow Items | -3.123 | -0.113 | |||
Issuance (Retirement) of Debt, Net | 2.373 | -0.289 | -0.164 | -0.204 | -0.062 |
Foreign Exchange Effects | 0.033 | -0.708 | -0.998 | -0.638 | -0.141 |
Net Change in Cash | 7.813 | -11.24 | -11.002 | -8.654 | -6.565 |
Issuance (Retirement) of Stock, Net | 10.748 | 0.1 | 0.055 | 0.04 | |
Deferred Taxes | 0.116 |
Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
---|---|---|---|---|---|---|
Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 22.4131 | 1659654 | 1401901 | 2023-05-17 | MED |
Ocumension Therapeutics | Corporation | 15.4621 | 1144945 | 0 | 2023-04-24 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 8.9243 | 660832 | 0 | 2023-03-31 | MED |
Caligan Partners, LP | Hedge Fund | 6.4657 | 478777 | 0 | 2023-05-17 | MED |
Eiswirth (Richard S Jr) | Individual Investor | 4.3555 | 322518 | 500 | 2023-04-24 | LOW |
HOOPP Investment Management | Pension Fund | 3.3762 | 250000 | 0 | 2023-03-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0071 | 148624 | 0 | 2023-03-31 | LOW |
Ashman Philip | Individual Investor | 1.8004 | 133315 | 0 | 2023-04-24 | MED |
Holland (David R) | Individual Investor | 1.4704 | 108880 | 500 | 2023-04-24 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.3693 | 101394 | -1100 | 2023-03-31 | HIGH |
Skibsted (Russell L) | Individual Investor | 1.0196 | 75500 | 58000 | 2023-03-26 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5167 | 38262 | 0 | 2023-03-31 | LOW |
Jones (John Philip) | Individual Investor | 0.4347 | 32186 | 372 | 2022-10-31 | |
Millennium Management LLC | Hedge Fund | 0.3884 | 28762 | 16799 | 2023-03-31 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.2639 | 19542 | 0 | 2023-03-31 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.2471 | 18300 | 0 | 2023-03-31 | LOW |
Perritt Capital Management, Inc. | Investment Advisor | 0.2431 | 18000 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.175 | 12962 | 438 | 2023-03-31 | LOW |
J.P. Morgan Securities LLC | Research Firm | 0.14 | 10364 | 9838 | 2023-03-31 | MED |
Snisarenko (John) | Individual Investor | 0.135 | 10000 | 0 | 2023-04-24 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group535K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$113M+
Ikmēneša ieguldījumu apjoms
$64M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Alimera Sciences, Inc. Company profile
Par Alimera Sciences, Inc.
Alimera Sciences, Inc. ir farmācijas uzņēmums. Uzņēmums nodarbojas ar recepšu oftalmoloģisko medikamentu komercializāciju un izstrādi. Tā koncentrējas uz slimībām, kas ietekmē acs aizmugurējo daļu jeb tīkleni. Uzņēmuma komerciālais produkts ILUVIEN ir intravitreālais implants, ar kuru ārstē pacientus, nepārtraukti ievadot mikrodevu nepatentēta kortikosteroīda fluocinolona acetonīda (FAc) acī līdz pat 36 mēnešiem. Uzņēmums nodarbojas ar diabētiskās makulas tūskas (DME) ārstēšanu. DME ir tīklenes slimība, kas skar diabēta slimniekus un var izraisīt smagu redzes zudumu un aklumu. ILUVIEN var lietot arī, lai novērstu recidīvu recidivējoša neinfekcioza uveīta, kas skar acs aizmugurējo segmentu (NIU-PS), gadījumā. Uzņēmums tieši tirgo ILUVIEN Amerikas Savienotajās Valstīs, Vācijā, Apvienotajā Karalistē, Portugālē un Īrijā.
Industry: | Biopharmaceuticals |
Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 535 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com